Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer
| Autor: | Kana Kobayashi, Taiji Tamura, Tomoaki Yamanishi, Takuji Yamagami, Norihiko Hamada, Miki Yasuoka, Kana Miyatake, Yoriko Murata, Mitsuhiko Miyamura, Kenta Ohgi, Yasuhiro Ogawa, Hitomi Iwasa, Rika Yoshimatsu, N. Aoyama |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research Radiosensitizer medicine.medical_specialty medicine.medical_treatment Sodium hyaluronate hydrogen peroxide 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine Adverse effect sodium hyaluronate radiosensitizer business.industry Therapeutic effect Cancer stage I primary breast cancer Articles medicine.disease Supraclavicular lymph nodes ultrasonographic guidance Radiation therapy 030104 developmental biology medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Kochi oxydol-radiation therapy for unresectable carcinomas II business Primary breast cancer |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2017.6074 |
| Popis: | Linac-based stereotactic radiotherapy has little effect on the majority of advanced neoplasms. Therefore, the novel radiosensitizer Kochi oxydol-radiation therapy for unresectable carcinomas (KORTUC) II, which contains hydrogen peroxide and sodium hyaluronate, was developed. The effectiveness of KORTUC II for the treatment of chemotherapy-resistant supraclavicular lymph node metastases, recurrent breast cancer and stage IV primary breast cancer has previously been demonstrated. The present study evaluated the safety and efficacy of KORTUC II for patients with stage I primary breast cancer. A total of 15 patients (age range, 40-76 years) were enrolled. The injection of 3 ml of KORTUC II agent was initiated from the sixth radiotherapy fraction and was performed twice a week, under ultrasonographic guidance. The therapeutic effects were evaluated by PET-CT and/or MRI examinations prior to and following KORTUC II treatment. All patients exhibited complete responses and the overall survival rate was 100% after a follow-up period of five years. The mean duration of follow-up at the end of March 2015 was 53 months. Based on these results, KORTUC II treatment exhibited marked therapeutic effects with satisfactory treatment outcomes and an acceptable extent of adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|